Trials / Completed
CompletedNCT06361576
Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada
Patients With Upper Gastrointestinal Adenocarcinoma Enrolled in a Patient Support Program to Receive Nivolumab in the Metastatic Setting: Real-World Data From Canada
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 700 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when treated with nivolumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | As per product label |
Timeline
- Start date
- 2023-09-05
- Primary completion
- 2024-01-25
- Completion
- 2024-01-25
- First posted
- 2024-04-12
- Last updated
- 2024-04-12
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06361576. Inclusion in this directory is not an endorsement.